SEC Comment Letter for MiNK Therapeutics, (INKT) — Nov 7, 2022
MiNK Therapeutics, Inc.
Date: Nov. 7, 2022 · CIK: 0001840229 · Accession: 0000000000-22-012111
AI Filing Summary & Sentiment
File numbers found in text: 333-268143
Letter
United States securities and exchange commission logo November 7, 2022 Jennifer S. Buell, Ph.D. President, Chief Executive Officer and Director MiNK Therapeutics, Inc. 149 Fifth Street, Suite 500 New York, NY 10010 Re:MiNK Therapeutics, Inc. Registration Statement on Form S-3 Filed November 3, 2022 File No. 333-268143 Dear Jennifer S. Buell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Zachary Blume, Esq.
Show Raw Text
United States securities and exchange commission logo
November 7, 2022
Jennifer S. Buell, Ph.D.
President, Chief Executive Officer and Director
MiNK Therapeutics, Inc.
149 Fifth Street, Suite 500
New York, NY 10010
Re:MiNK Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 3, 2022
File No. 333-268143
Dear Jennifer S. Buell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Zachary Blume, Esq.